

Not your typical


ABO and Rh (D) type

By: Priscilla Moreira

Australia Red Cross Blood Service - Victoria

Case 1: Patient Y

- 65 year old male
- No previous transfusion



Initial group

ABO								Rh (D)				Group		
Cell group				Serum group				IgM	IgM/IgG		Control		ABO	Rh
-A	-B	-AB	-A1	A1	A2	B	O		I.S.	IAT	I.S.	IAT		
0	4+	4+	0	1+	0	0	0	4+	4+	/	0	/	B	Pos

B forward group and weak reactions in the reverse group

Reverse group and Antibody Screen

Australian Red Cross Blood Service

Extended Reagent Red Cell Panel

	Additional Comments	No	IS	IS' RT	5' 4°C IAT	RAM		
	A ₁	1	1+S	1+S	2+	1+		
	A ₁	2	1+S	1+S	2+	0		
	A ₂	3	0	0	2+	0		
	A ₂	4	0	0	2+	0		
	SC1 0	5	0	0	0	0		
	SC2 0	6	0	0	0	0		
	SC3 0	7	0	0	0	0		
	B	8	0	0	0	0		
	B	9	0	0	0	0		
	AUTO	10	0	0	0	0		
		11						
		12						
		13						
		14						
		15						
Pos Control: R ₁			0	0	0	1+S		
Neg Control: r _r			0	0	0	0		

Anti-A in the plasma, reacting with both A₁ and A₂ cells at 4°C

Various ABO typing sera

Reagent Set	FORWARD GROUP				REVERSE GROUP				Testing method
	Anti-A	Anti-B	Anti-AB	Anti-A1	A1	A2	B	O	
Reagents 1	0	4+	4+	0	1+	0	0	0	tube
Reagents 2	★ 1+	4+			1+s		0		card
Reagents 3	0	4+	4+						tube
Reagents 4	★ 2+	4+	4+						tube
Reagents 5	0	4+			1+s		0		card

Adsorption and elution

- Patient's cells failed to adsorb and elute anti-A.
- Unlikely for group to be a weak subgroup of A.

Product inserts, clones used and specific reagent performance characteristics

Reagent Set	FORWARD GROUP				Testing method	Anti- A Clones
	Anti-A	Anti-B	Anti-AB	Anti-A1		
Reagents 1	0	4+	4+	0	tube	4E7, 8F2
Reagents 2	1+	4+	4+	0	card	MHO4, 3D3
Reagents 3	0	4+	4+	0	tube	Cell line Birma - 1
Reagents 4	2+	4+	4+	0	tube	A003
Reagents 5	0	4+	4+	0	card	Cell line A5

B(A) phenomenon

- Not frequently encountered - about 1 per year.
- Can be attributed to amino acid polymorphisms in the B glycosyltransferase near (Pro234Ala) or at critical amino acids (Ser235Gly).

Table 2.18 Enzymes with dual A- and B-transferase activity: amino acid substitutions at the four positions (176, 235, 266, 268) characteristic of A and B and at positions 214 and 234.

Phenotype*	Alleles	Amino acids						Shorthand	References
		176	214	234	235	266	268		
A ₁	A101 or A102	Arg	Met	Pro	Gly	Leu	Gly	AAAA	
B	B	Gly	Met	Pro	Ser	Met	Ala	BBBB	
B(A)	B(A)01 & B(A)03	Gly	Met	Pro	Gly	Met	Ala	BABB	[269,293]
B(A)	B(A)02	Gly	Met	Ala	Ser	Met	Ala	BBBB	[379]
B(A)	B(A)04	Gly	Val	Pro	Ser	Met	Ala	BBBB	[380]
B(A)	B(A)05	Gly	Thr	Pro	Ser	Met	Ala	BBBB	[380]

- The B glycosyltransferase in these individuals has an increased capacity to use UDP-N-acetylgalactosamine, as well as UDP-galactose, resulting in small amounts of aberrant A antigen.

Transfusion

- Patient Y should be treated as group B.

Case 2: Patient X

- 92 year old female with a pelvic fracture.
- Grouped as O Rh(D) Pos.

ABO								Rh (D)				
Cell group				Serum group				IgM	IgM/IgG		Control	
-A	-B	-AB	-A1	A1	A2	B	O		I.S.	IAT	I.S.	IAT
○	○	○	○	4 ⁺	4 ⁺	3 ⁺	○	4 ⁺	3 ⁺ s	3 ⁺ s	○	○

- R1r, DAT negative.

11 Reagent Red Cell panel

Patient X

Cell No	Reference No	RH							KEL			FY		JK		MNS				P1PK	LE		LU	CO	Additional Typings	Cell No	Results		
		Rh Phen.	D	C	E	c	e	C ^w	K	k	Kp ^a	Fy ^a	Fy ^b	JK ^a	JK ^b	M	N	S	s	P1	Le ^a	Le ^b	Lu ^a	Co ^b			CAT IAT	CAT IAT	
1	2083263	R ₁ ^w R ₁	+	+	0	0	+	+	0	+	+	+	0	+	0	+	0	+	+	0	+	0	+	0		1	3 ⁺		
2	2146231	R ₁ R ₁	+	+	0	0	+	0	+	+	0	+	0	0	+	+	0	+	0	+	0	+	0	+	*Cs(a-)	2	3 ⁺		
3	2195612	R ₁ R ₁	+	+	0	0	+	0	0	+	0	0	+	0	+	0	+	0	+	0	0	0	+	0		3	3 ⁺		
4	2002472	R ₂ R ₂	+	0	+	+	0	0	0	+	0	0	+	+	0	0	+	0	+	+ ^s	0	+	0	0		4	3 ⁺		
5	2013679	R ₂ R ₂	+	0	+	+	0	0	0	+	+	+	0	+	+	+	0	+	+	0	0	0	0	0		5	2 ⁺		
6	2053551	r ^r r	0	+	0	+	+	0	0	+	0	+	0	+	+	+	0	0	+	0	0	+	0	0	^Ch(a-)	6	0		
7	2260094	r ^r r	0	0	+	+	+	0	0	+	0	0	+	0	+	+	0	+	0	+	+	0	+	0	*M ₁ +	7	0		
8	1420103	rr	0	0	0	+	+	0	+	+	0	0	+	+	0	+	+	0	+	+ ^s	+	0	0	0		8	3 ⁺		
9	2059833	rr	0	0	0	+	+	0	0	+	0	+	+	+	0	+	0	0	+	0	0	0	0	0		9	0		
10	2058202	rr	0	0	0	+	+	0	0	+	0	+	0	+	0	+	0	+	0	+	0	+	0	0		10	0		
11	2056302	rr	0	0	0	+	+	0	0	+	0	+	0	0	+	0	+	0	+	+ ^w	+	0	0	+		11	0		
Auto																									Auto	0		0	
8	4086345	rr	0	0	0	+	+	0	+	+	0	+	0	+	0	+	0	+	0	+	0	+	0	0	B: 2648 100 01 Exp: 20.2.17	8		3 ⁺	
8	3175965	rr	0	0	0	+	+	0	+	+	0	+	+	+	+	+	0	+	+	+ ^s	+	0	0	0	B: 0659 965 01 Exp: 14.3.17	8		3 ⁺	
9	11976750	rr	0	0	0	+	+	0	+	+	+	+	+	+	+	+	+	+	+	+	0	+	+	0	B: 8660 100 01 Exp: 7.3.17	9		0	
Reference No																									Reference No				

Anti-D

Anti-K

Auto neg

But!

- Patient X was Rh(D) pos R1r
- So was this a case of anti-D in a partial D individual or
- An Rh(D) positive patient with anti-LW....

LW

- LW and D are different antigens but phenotypically related.
- LW is more strongly expressed on D positive than D negative adult cells.
- Rh null cells which lack all Rh antigens, also lack LW.
- LW is strongly expressed on red cells of neonates regardless of the D type.

Rh (D) negative cord cell

Patient X

Cell No	Reference No	RH						KEL			FY		JK		MNS			P1PK	LE		LU	CO	Additional Typings	Cell No	Results				
		Rh Phen.	D	C	E	c	e	C ^w	K	k	Kp ^a	Fy ^a	Fy ^b	Jk ^a	Jk ^b	M	N	S	s	P1	Le ^a	Le ^b			Lu ^a	Co ^b	CAT IAT	CAT IAT	
1	2083263	R ₁ ^w R ₁	+	+	0	0	+	+	0	+	+	0	+	0	+	0	+	+	0	+	0	+	0	+	1	3 ⁺			
2	2146231	R ₁ R ₁	+	+	0	0	+	0	+	+	0	+	0	0	+	+	0	+	0	+	+	0	+	0	2	3 ⁺			
3	2195612	R ₁ R ₁	+	+	0	0	+	0	0	+	0	0	+	0	+	0	+	0	+	0	0	+	0	0	3	3 ⁺			
4	2002472	R ₂ R ₂	+	0	+	+	0	0	0	+	0	0	+	+	0	0	+	0	+	+	s	0	+	0	0	4	3 ⁺		
5	2013679	R ₂ R ₂	+	0	+	+	0	0	0	+	+	+	0	+	+	+	0	+	+	+	0	0	0	0	0	5	2 ⁺		
6	2053551	r ⁺ r	0	+	0	+	+	0	0	+	0	+	0	+	+	+	0	0	+	0	0	+	0	0	6	0			
7	2260094	r ⁺ r	0	0	+	+	+	0	0	+	0	0	+	0	+	+	0	+	0	+	+	0	+	0	7	0			
8	1420103	rr	0	0	0	+	+	0	+	0	0	+	+	0	+	+	0	+	+	+	s	+	0	0	8	3 ⁺			
9	2059833	rr	0	0	0	+	+	0	0	+	0	+	+	0	+	0	0	+	0	0	0	0	0	0	9	0			
10	2058202	rr	0	0	0	+	+	0	0	+	0	+	0	+	0	+	0	+	0	+	+	0	+	0	10	0			
11	2056302	rr	0	0	0	+	+	0	0	+	0	+	0	0	+	0	+	0	+	+	w	+	0	0	+	11	0		
Auto																									Auto	0	0		
8	4086345	rr	0	0	0	+	+	0	+	0	+	0	+	0	0	+	0	+	0	+	0	+	0	0	8		3 ⁺		
8	3175965	rr	0	0	0	+	+	0	+	0	+	+	+	+	+	0	+	+	+	+	s	+	0	0	0	8		3 ⁺	
9	11976750	rr	0	0	0	+	+	0	0	+	+	+	+	+	+	+	+	+	+	+	+	0	+	+	0	9		0	
Reference No																									Reference No				
Ab1																									Ab1				
Ab2																									Ab2				
Ab3																									Ab3				
		Rh Phen.	D	C	E	c	e	C ^w	K	k	Kp ^a	Fy ^a	Fy ^b	Jk ^a	Jk ^b	M	N	S	s	P1	Le ^a	Le ^b	Lu ^a	Co ^b	Cord				
																										0 Rh(D) neg Lot: O-Cord 250117v1 Exp: 27.3.17			
This product is manufactured from blood donated by voluntary donors to the Australian Red Cross Blood Service (ARCBS).																													
Note: Cells 6, 7 and 8 form the RhD Negative Screening Cell Subset, formulated for antenatal RhD antibody screening in the presence of Prophylactic Anti-D.																													

This product is manufactured from blood donated by voluntary donors to the Australian Red Cross Blood Service (ARCBS).

Note: Cells 6, 7 and 8 form the RhD Negative Screening Cell Subset, formulated for antenatal RhD antibody screening in the presence of Prophylactic Anti-D.

Non reactive

Range of anti-D reagents

	IgM		IgM		IgM		IgM		IgM/IgG			Rh Control			IgM/IgG		
No.	<i>ctrl</i>		<i>ctrl</i>												<i>15' @ 37</i>		
	IS	37C	IS	37C	IS	37C	IS	37C	IS	37C	IAT	IS	37C	IAT	IS	37C	IAT
R ₁ r	4 ⁺	0	4 ⁺	0											4 ⁺	/	/
D ⁺ _w	2 ⁺ ^s	0	2 ⁺	0											2 ⁺	1 ⁺	3 ⁺
rr	0	0	0	0											0	0	0
Patient X	4 ⁺	0	4 ⁺	0											4 ⁺	/	/

Partial Rh (D) typing kit

Patient X

Check our website for the most up-to-date version of the reaction profile, supplementary information and recent findings. www.quotientbd.com

Kit ID	Anti-D Cell Line	Weak D Type 1 and 2 ^o	DII & DNU	DIII	DIV	DV*	DCS	DVI	DVII	DOL	DFR	DMH	DAR [†]	DAR-E	DHK ² & DAU-4	DBT	Ro ^{Har} 5	Pos Cont.	Neg Cont.	Test Result
A	LHM76/58	+	+	+	+	+/-	+	0	+	+	+	+	+	0	0	0	(+)/0	4+	0	3+
B	LHM76/59	+	+	+	0	+	+	+	+	+	+	+	+	+	+	0	0	4+	0	4+
C	LHM174/102	(+)/0	+	+	0	0	+	0	+	0	0	+	0	0	0	0	0	4+	0	+/-
D	LHM50/2B	+	+	+	+	+	+	0	+	+	+	+	+	+	+	0	0	4+	0	4+
E	LHM169/81	+	+	+	0	0	+	0	+	+	+	+	0	0	0	0	0	4+	0	3+
F	ESD1	+	+	+	0	+	+	+	+	+	+	+	+	+	+	0	0	4+	0	3+
G	LHM76/55	+	+	+	0	+	+	+	+	+	+	+	+	+	+	0	0	4+	0	3+
H	LHM77/64	+	0	+	0	+	+	+	+	+	+	+	+	+	+/-	0	0	4+	0	2+
I	LHM70/45	(+)/0	+	+	0	0	0	0	+	0	0	0	0	0	0	0	0	4+	0	+/-
J	LHM59/19	+	+	+	+	+	+	0	0	0	0	(+)	0	(+)	+	+	0	4+	0	2+
K	LHM169/80	+	+	+	+	+	+	0	+	+	+	+	+	+	0	0	0	4+	0	4+
L	LHM57/17	+	+	+	+	+	0	0	+	+	0	+	+	0	0	+	0	3+	0	0

*Refer to website for supplementary information

All strongly positive

Human Source anti-D

[illegible]

Non reactive

RHD genotyping – serological findings confirmed!


DNA extracted from the EDTA sample was genotyped using the BioArray Solutions RHD BeadChip™ Kit.

The Immucor BioArray System™ analyses the signal intensity for each specific marker to determine the predicted RhD phenotype.

RhD Phenotypical Variant: DIIIc (hemizygous or homozygous)

Partial D Category DIII

- This is a result of the exon 3 of RHD being replaced with that of the RHCE.



Partial D Category DIII

- The DIII phenotype is not frequently encountered in our lab.
- DIII red cells although reactive with all monoclonal anti-D must lack at least one D epitope resulting in the ability to make allo anti-D.
- Patients with this phenotype should be treated as Rh (D) negative for transfusion purposes and in the antenatal setting.

References

- Carton JP, Rouger P 1995. Blood Cell Biochemistry. Molecular Basis of Human Blood Group Antigens. New York and London: Plenum Press.
- Daniels G 2013. Human Blood Groups. New Jersey: Wiley-Blackwell.
- Daniels G and Bromilow I 2010. Essential Guide to Blood Groups. New Jersey: Wiley-Blackwell.
- Roback J, Combs MR, Grossman BJ, Hillyer CD 2008. Technical Manual. USA: AABB.

Acknowledgements

*Australian Governments fund the Australian Red Cross Blood Service
for the provision of blood, blood products and services to the Australian
community*